Human MicrobiomeNCT03668015
Xylitol and Sorbitol Effects on the Oral Microbiome
A study testing Xylitol then Sorbitol gum and Sorbitol then Xylitol gum in people with Human Microbiome, run by The University of The West Indies.
Trial summary
Chewing gum containing xylitol may help prevent caries by reducing levels of mutans streptococci (MS) and lactobacilli in saliva and plaque. Very little is known about other species which are possibly beneficial to oral health. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Human Microbiome
- What is being tested?
- Xylitol then Sorbitol gum and Sorbitol then Xylitol gum
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 29 participants
- Where
- No sites listed yet
- Study dates
- 5 Mar 2015to 4 Jun 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- To be eligible, subjects must have been 18 years and over, have had at least 20 teeth, provided written informed consent and been willing to comply with study procedures
Who cannot join
- Subjects with systemic, infectious or inflammatory diseases or taking medicines, antibiotics or fluoride in the last month, habitual consumers of xylitol / sorbitol-containing products and mouth rinses, with abnormal salivary flow (<1ml / min), pregnant, on contraceptive pills, or with abnormal dietary habits were excluded
About this study
Official title: Xylitol and Sorbitol Effects on the Microbiome of Saliva and Plaque
Chewing gum containing xylitol may help prevent caries by reducing levels of mutans streptococci (MS) and lactobacilli in saliva and plaque. Very little is known about other species which are possibly beneficial to oral health. In this study, the investigators employed high-throughput sequencing of the 16S ribosomal ribonucleic acid (rRNA) gene to profile microbial communities of saliva and plaque following short-term consumption of xylitol and sorbitol containing chewing gum. Participants (n = 30) underwent a washout period and were randomly assigned to one of two groups. Each group chewed either xylitol or sorbitol gum for 3 weeks, before undergoing a second four-week washout period after which they switched to the alternate gum for three weeks.
Read the detailed description
Subjects: Study protocols were approved by the Ethics Committees of the UWI, St. Augustine. Thirty healthy volunteers from The University of the West Indies (UWI), St. Augustine, Trinidad were enrolled in the study. To be eligible, subjects must have had at least 20 teeth, provided written informed consent and been willing to comply with study procedures. Subjects with systemic, infectious or inflammatory diseases or taking medicines, antibiotics or fluoride in the last month, habitual consumers of xylitol / sorbitol-containing products and mouth rinses, with abnormal salivary flow (<1ml / min), pregnant, on contraceptive pills, or with abnormal dietary habits were excluded. Consent obtained at the initial visit was verified at the second visit, prior to sample collection. The subjects were examined in the dental chair after thorough medical and dental histories were recorded. The clinical examination involved examination of the soft tissues and then dental hard tissue charting for presence of decayed, missing or filled teeth. No radiographs were used. The presence of untreated dental caries or periodontitis were not used as exclusion criteria. The decayed, missing, and filled teeth for each individual at the initial visit was documented for calculation of the index of decayed-missing-filled permanent teeth (DMFT) score.
Chewing gums: Xylitol gum (Epic Spearmint; 1.5g/pellet) designated Gum X contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Gum S (Eclipse Spearmint), was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Gums were packed in colour-coded containers. Codes were kept confidential from the participants and researchers who interacted with them until study completion.
Study design: This prospective cross-over, double-blind, randomised study lasted 14 weeks (March - June, 2015). Throughout, subjects were instructed not to use mouthwashes or xylitol products, to consume a normal diet, continue their usual tooth brushing and to report use of antimicrobial medications. Subjects reporting the latter were dropped.
Subjects were randomly allocated to two groups, A and B (see Figure 1). Both groups entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Gum X and Group B used Gum S (2 gum pieces, 3 times daily after meals for 6 minutes). Both groups then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum S and Group B used Gum X for 3 weeks.
Sample collection: Saliva and plaque were collected from participants immediately before and after each treatment period (Figure 1). Subjects were instructed not to brush their teeth or use any other oral hygiene procedures at least 24 hours before sample collection, and not to eat or drink at least 1 hour before. For saliva collection, subjects chewed sterile paraffin wax and whole saliva produced was collected for 5 minutes in sterile tubes. The subject was asked to drool into the labelled 50ml collection tube (Falcon sterile, conical polypropylene tube with flat-top screw cap). This process was repeated multiple times in order to collect larger volumes of saliva (2-5 ml). The saliva was transferred via sterile pipettes into labelled sterile centrifuge tubes which were stored at -70˚C until use.
Supragingival plaque was collected with a curette from 2 molars (#16 and #36), 2 premolars (#24 and #44), and 2 incisors (#21 and #41); Plaque collection involved using a Gracey curette to remove all of the supragingival plaque from the buccal surface of the selected index tooth with as many strokes as necessary. The curette tip was immersed in the sterile DNase-free Tris-EDTA (TE) buffer in the centrifuge tube for 4-5 seconds. The face of the curette was wiped on the inside edge of the collection tube and then wiped off with sterile gauze so as to not let the buffer on the tip go into patient's mouth. The site was then immediately sampled again using the same procedure. The lid on the tube was replaced and then the tube shaken for 4-5 seconds in an attempt to maximize dispersion of the specimen in the fluid. The tube was immediately placed on ice in a Ziploc bag and stored at -70˚C until use. Samples were labelled by group (A/B), treatment period (1/2), gum used (X/S in the case of those samples collected at the end of a given treatment period) and type (saliva (s) or plaque (p)). Samples (n=232) were then shipped on dry ice to the J. Craig Venter Institute (JCVI) USA, La Jolla campus for DNA extraction and sequencing.
DNA extraction: Samples were thawed at 4˚C and vortexed thoroughly prior to DNA extraction from 500ul of saliva or plaque suspension using bead beating Lysing Matrix B tubes (MPBio Inc.), then lysozyme digest, phenol/chloroform isoamyl alcohol extraction and ethanol precipitation. Precipitated DNA was resuspended in 1x TE buffer.
Library Preparation and Sequencing: DNA from each sample was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Inc, Waltham, MA). Amplicons were generated using adaptor and barcode ligated polymerase chain reaction (PCR) primers targeting the V4 region of the 16S rDNA gene (16S) and purified using Qiaquick PCR purification kits (Qiagen, Inc) following manufacturer's instructions. Purified amplicons were quantified using SybrGold (Thermo Fisher Scientific, Inc, Waltham, MA), normalized to ensure equimolar quantities of each sample, and pooled in preparation for Illumina MiSEQ sequencing. The 16S library pool was sequenced using the Illumina MiSEQ dual index 2x250bp V2 chemistry kit according to manufacturer's specifications.
16S RNA sequence data processing: Sequences for each sample were binned according to corresponding dual indices and exported as individual .fastq files using CASAVA v1.8.2 (Illumina Inc. La Jolla, CA). Sequences were processed to ensure that only quality sequences were retained, as stringent settings were kept to ensure no barcode mismatches were permitted during demultiplexing. Processed sequences were applied to the Infernal pipeline [35] for additional quality control (QC) checks. Bacterial sequences were taxonomically assigned based on the Genomic-based 16S ribosomal RNA Database (GRD; http://metasystems.riken.jp/grd/).
Statistical analyses. Distribution by age, sex and DMFT score for subjects in groups A and B were compared using independent-samples T- test, Pearson's Chi-Squared test and Wilcoxon rank sum test respectively, with a cut-off of p <0.05. To avoid possible sequence errors, operational taxonomic unit (OTU) count tables were filtered such that OTUs present in fewer than 0.1% in all samples were discarded. OTU tables were then transformed to relative abundances before community analyses were performed using the R statistical computing language (Cite R). Kruskal-Wallis test was used to assess statistical significance in microbial community composition across treatments. Wilcoxon test was used for pairwise comparison.
- Conditions
- Human Microbiome
- Being tested
- Xylitol then Sorbitol gum, Sorbitol then Xylitol gum
- Keywords
- caries, bacteria, saliva, plaque, microbial ecology
- Medical subject headings
- Plaque, Amyloid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Xylitol then Sorbitol gumOther
Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
Sorbitol then Xylitol gumOther
Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
| Study group | Role | What they receive |
|---|---|---|
| Group A (Xylitol then sorbitol gum) | Experimental | Subjects were randomly allocated to a group and entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol Receives: Other: Xylitol then Sorbitol gum |
| Group B (Sorbitol then xylitol gum) | Experimental | Subjects were randomly allocated to a group and entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum. Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol Receives: Other: Sorbitol then Xylitol gum |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oral microbiome composition
Profile microbial communities of saliva and plaque based high-throughput sequencing of the 16S rRNA gene.
Measured: 14 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2018
- Study start5 Mar 2015
- Primary completion4 Jun 2015
- Study completion4 Jun 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human MicrobiomeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- The University of The West Indies
- Sponsor type
- University, hospital or other
- Collaborators
- J. Craig Venter Institute
- Responsible party
- Principal investigator, Reisha Rafeek, The University of The West Indies
- Investigators
- Reisha Rafeek, MSc, BDS, Principal investigator, The University of The West Indies
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03668015
- Sponsor's protocol ID
- CRP.3.MAR14.7
- Status last verified
- Sep 2021
- First submitted
- 10 Sep 2018
- Last updated
- 5 Oct 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Xylitol and Sorbitol Effects on the Microbiome of Saliva and Plaque
- ClinicalTrials.gov ID
- NCT03668015
- Acronym / sponsor ID
- CRP.3.MAR14.7
- Conditions
- Human Microbiome
- Keywords
- caries, bacteria, saliva, plaque, microbial ecology
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- The University of The West IndiesUniversity, hospital or other
- Collaborators
- J. Craig Venter Institute
- Study start
- 5 Mar 2015 (actual)
- Primary completion
- 4 Jun 2015 (actual)
- Study completion
- 4 Jun 2015 (actual)
- First posted
- 12 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chewing gum containing xylitol may help prevent caries by reducing levels of mutans streptococci (MS) and lactobacilli in saliva and plaque. Very little is known about other species which are possibly beneficial to oral health. In this study, the investigators employed high-throughput sequencing of the 16S ribosomal ribonucleic acid (rRNA) gene to profile microbial communities of saliva and plaque following short-term consumption of xylitol and sorbitol containing chewing gum. Participants (n = 30) underwent a washout period and were randomly assigned to one of two groups. Each group chewed either xylitol or sorbitol gum for 3 weeks, before undergoing a second four-week washout period after which they switched to the alternate gum for three weeks.
Detailed description
Subjects: Study protocols were approved by the Ethics Committees of the UWI, St. Augustine. Thirty healthy volunteers from The University of the West Indies (UWI), St. Augustine, Trinidad were enrolled in the study. To be eligible, subjects must have had at least 20 teeth, provided written informed consent and been willing to comply with study procedures. Subjects with systemic, infectious or inflammatory diseases or taking medicines, antibiotics or fluoride in the last month, habitual consumers of xylitol / sorbitol-containing products and mouth rinses, with abnormal salivary flow (<1ml / min), pregnant, on contraceptive pills, or with abnormal dietary habits were excluded. Consent obtained at the initial visit was verified at the second visit, prior to sample collection. The subjects were examined in the dental chair after thorough medical and dental histories were recorded. The clinical examination involved examination of the soft tissues and then dental hard tissue charting for presence of decayed, missing or filled teeth. No radiographs were used. The presence of untreated dental caries or periodontitis were not used as exclusion criteria. The decayed, missing, and filled teeth for each individual at the initial visit was documented for calculation of the index of decayed-missing-filled permanent teeth (DMFT) score.
Chewing gums: Xylitol gum (Epic Spearmint; 1.5g/pellet) designated Gum X contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Gum S (Eclipse Spearmint), was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Gums were packed in colour-coded containers. Codes were kept confidential from the participants and researchers who interacted with them until study completion.
Study design: This prospective cross-over, double-blind, randomised study lasted 14 weeks (March - June, 2015). Throughout, subjects were instructed not to use mouthwashes or xylitol products, to consume a normal diet, continue their usual tooth brushing and to report use of antimicrobial medications. Subjects reporting the latter were dropped.
Subjects were randomly allocated to two groups, A and B (see Figure 1). Both groups entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Gum X and Group B used Gum S (2 gum pieces, 3 times daily after meals for 6 minutes). Both groups then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum S and Group B used Gum X for 3 weeks.
Sample collection: Saliva and plaque were collected from participants immediately before and after each treatment period (Figure 1). Subjects were instructed not to brush their teeth or use any other oral hygiene procedures at least 24 hours before sample collection, and not to eat or drink at least 1 hour before. For saliva collection, subjects chewed sterile paraffin wax and whole saliva produced was collected for 5 minutes in sterile tubes. The subject was asked to drool into the labelled 50ml collection tube (Falcon sterile, conical polypropylene tube with flat-top screw cap). This process was repeated multiple times in order to collect larger volumes of saliva (2-5 ml). The saliva was transferred via sterile pipettes into labelled sterile centrifuge tubes which were stored at -70˚C until use.
Supragingival plaque was collected with a curette from 2 molars (#16 and #36), 2 premolars (#24 and #44), and 2 incisors (#21 and #41); Plaque collection involved using a Gracey curette to remove all of the supragingival plaque from the buccal surface of the selected index tooth with as many strokes as necessary. The curette tip was immersed in the sterile DNase-free Tris-EDTA (TE) buffer in the centrifuge tube for 4-5 seconds. The face of the curette was wiped on the inside edge of the collection tube and then wiped off with sterile gauze so as to not let the buffer on the tip go into patient's mouth. The site was then immediately sampled again using the same procedure. The lid on the tube was replaced and then the tube shaken for 4-5 seconds in an attempt to maximize dispersion of the specimen in the fluid. The tube was immediately placed on ice in a Ziploc bag and stored at -70˚C until use. Samples were labelled by group (A/B), treatment period (1/2), gum used (X/S in the case of those samples collected at the end of a given treatment period) and type (saliva (s) or plaque (p)). Samples (n=232) were then shipped on dry ice to the J. Craig Venter Institute (JCVI) USA, La Jolla campus for DNA extraction and sequencing.
DNA extraction: Samples were thawed at 4˚C and vortexed thoroughly prior to DNA extraction from 500ul of saliva or plaque suspension using bead beating Lysing Matrix B tubes (MPBio Inc.), then lysozyme digest, phenol/chloroform isoamyl alcohol extraction and ethanol precipitation. Precipitated DNA was resuspended in 1x TE buffer.
Library Preparation and Sequencing: DNA from each sample was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Inc, Waltham, MA). Amplicons were generated using adaptor and barcode ligated polymerase chain reaction (PCR) primers targeting the V4 region of the 16S rDNA gene (16S) and purified using Qiaquick PCR purification kits (Qiagen, Inc) following manufacturer's instructions. Purified amplicons were quantified using SybrGold (Thermo Fisher Scientific, Inc, Waltham, MA), normalized to ensure equimolar quantities of each sample, and pooled in preparation for Illumina MiSEQ sequencing. The 16S library pool was sequenced using the Illumina MiSEQ dual index 2x250bp V2 chemistry kit according to manufacturer's specifications.
16S RNA sequence data processing: Sequences for each sample were binned according to corresponding dual indices and exported as individual .fastq files using CASAVA v1.8.2 (Illumina Inc. La Jolla, CA). Sequences were processed to ensure that only quality sequences were retained, as stringent settings were kept to ensure no barcode mismatches were permitted during demultiplexing. Processed sequences were applied to the Infernal pipeline [35] for additional quality control (QC) checks. Bacterial sequences were taxonomically assigned based on the Genomic-based 16S ribosomal RNA Database (GRD; http://metasystems.riken.jp/grd/).
Statistical analyses. Distribution by age, sex and DMFT score for subjects in groups A and B were compared using independent-samples T- test, Pearson's Chi-Squared test and Wilcoxon rank sum test respectively, with a cut-off of p <0.05. To avoid possible sequence errors, operational taxonomic unit (OTU) count tables were filtered such that OTUs present in fewer than 0.1% in all samples were discarded. OTU tables were then transformed to relative abundances before community analyses were performed using the R statistical computing language (Cite R). Kruskal-Wallis test was used to assess statistical significance in microbial community composition across treatments. Wilcoxon test was used for pairwise comparison.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A (Xylitol then sorbitol gum) | Experimental | Other: Xylitol then Sorbitol gumSubjects were randomly allocated to a group and entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol |
| Group B (Sorbitol then xylitol gum) | Experimental | Other: Sorbitol then Xylitol gumSubjects were randomly allocated to a group and entered a 4-week "washout period" during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum. Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- To be eligible, subjects must have been 18 years and over, have had at least 20 teeth, provided written informed consent and been willing to comply with study procedures
Key exclusion criteria (1 listed)
- Subjects with systemic, infectious or inflammatory diseases or taking medicines, antibiotics or fluoride in the last month, habitual consumers of xylitol / sorbitol-containing products and mouth rinses, with abnormal salivary flow (<1ml / min), pregnant, on contraceptive pills, or with abnormal dietary habits were excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Xylitol then Sorbitol gumXylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. | Other | Group A (Xylitol then sorbitol gum) |
| Sorbitol then Xylitol gumSorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. | Other | Group B (Sorbitol then xylitol gum) |
Primary outcome
Oral microbiome composition
Time frame: 14 weeks
Profile microbial communities of saliva and plaque based high-throughput sequencing of the 16S rRNA gene.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2021.
- Individual participant dataSharing planned: No
Related trials for Human Microbiome
Active, not recruitingObservational study
Guangzhou Preterm and Term Birth Cohort Study
Preterm Birth, Neurodevelopmental Disorders
Active, not recruitingObservational study
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
Human Papilloma Virus, Vaginal Flora Imbalance
RecruitingObservational study
Pulmonary Immune Cell-microbiome Interactions in ARDS
ARDS, Human
Recruiting
Assessing the Potential Role of the Gut Microbiome in Modulating Physical Abilities in Humans
Physical Abilities, FMT
Active, not recruitingObservational study
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
Dysbiosis, Clostridium Difficile
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Reisha Rafeek, MSc, BDS principal investigator
The University of The West Indies
Questions about this trial
What is this clinical trial studying?
A study testing Xylitol then Sorbitol gum and Sorbitol then Xylitol gum in people with Human Microbiome, run by The University of The West Indies.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oral microbiome composition (time frame: 14 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2021.